New Single-Shot drug may protect kids on chemo from dangerous infections

NCT ID NCT06926751

Recruiting now Disease control Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a single injection of Telpegfilgrastim works better than daily Filgrastim shots to prevent fever and low white blood cells in children and young adults (ages 6-24) with solid tumors receiving strong chemotherapy. About 132 participants will receive either drug after each chemo cycle and be monitored for infections, side effects, and treatment delays. The goal is to find a safer, more convenient way to manage chemotherapy side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer chemotherapy-induced toxicity neutropenia prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADOLESCENT CHEMOTHERAPY INDUCED NEUTROPENIA CHILDREN SOLID TUMORS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••